Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate

Logo poskytovatele
Logo poskytovatele
Logo poskytovatele
Logo poskytovatele
Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Přírodovědeckou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

NEMERGUT Michal MARQUES Sérgio Manuel UHRÍK Lukáš VÁŇOVÁ Tereza NEZVEDOVÁ Markéta GADARA Darshak Chandulal JHA Durga TULIS Jan NOVÁKOVÁ Veronika PLANAS IGLESIAS Joan KUNKA Antonín LEGRAND Anthony Thomas P HŘÍBKOVÁ Hana POSPÍŠILOVÁ Veronika SEDMÍK Jiří RAŠKA Jan PROKOP Zbyněk DAMBORSKÝ Jiří BOHAČIAKOVÁ Dáša SPÁČIL Zdeněk HERNYCHOVÁ Lenka BEDNÁŘ David MAREK Martin

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj Molecular Neurodegeneration
Fakulta / Pracoviště MU

Přírodovědecká fakulta

Citace
www https://doi.org/10.1186/s13024-023-00620-9
Doi http://dx.doi.org/10.1186/s13024-023-00620-9
Klíčová slova Apolipoprotein E; Alzheimer’s disease; Neurodegeneration; Aggregation; Cerebral organoids; Molecular dynamics; HDX-MS; Protein crystallography; Proteomics; Lipidomics; Tramiprosate; 3-sulfopropanoic acid
Přiložené soubory
Popis Background Apolipoprotein E (ApoE) epsilon 4 genotype is the most prevalent risk factor for late-onset Alzheimer's Disease (AD). Although ApoE4 differs from its non-pathological ApoE3 isoform only by the C112R mutation, the molecular mechanism of its proteinopathy is unknown. Methods Here, we reveal the molecular mechanism of ApoE4 aggregation using a combination of experimental and computational techniques, including X-ray crystallography, site-directed mutagenesis, hydrogen-deuterium mass spectrometry (HDX-MS), static light scattering and molecular dynamics simulations. Treatment of ApoE epsilon 3/epsilon 3 and epsilon 4/epsilon 4 cerebral organoids with tramiprosate was used to compare the effect of tramiprosate on ApoE4 aggregation at the cellular level. Results We found that C112R substitution in ApoE4 induces long- distance (> 15 A) conformational changes leading to the formation of a V-shaped dimeric unit that is geometrically different and more aggregation-prone than the ApoE3 structure. AD drug candidate tramiprosate and its metabolite 3-sulfopropanoic acid induce ApoE3-like conformational behavior in ApoE4 and reduce its aggregation propensity. Analysis of ApoE epsilon 4/epsilon 4 cerebral organoids treated with tramiprosate revealed its effect on cholesteryl esters, the storage products of excess cholesterol. Conclusions Our results connect the ApoE4 structure with its aggregation propensity, providing a new druggable target for neurodegeneration and ageing.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info